| 1 |
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Barbato E, Pizzi C. Reply to SGLT-2 inhibitors: Post-infarction interventional effects. Pharmacol Res 2023;189:106664. [PMID: 36642618 DOI: 10.1016/j.phrs.2023.106664] [Reference Citation Analysis]
|
| 2 |
Vazirian F, Sadeghi M, Wang D, Javidi Dashtbayaz R, Gholoobi A, Samadi S, Mohammadpour AH. Correlation between osteoprotegerin and coronary artery calcification in diabetic subjects: a systematic review of observational studies. BMC Cardiovasc Disord 2023;23:96. [PMID: 36809976 DOI: 10.1186/s12872-023-03123-z] [Reference Citation Analysis]
|
| 3 |
He L, Zheng W, Li Z, Kong W, Zeng T. Association of four lipid-derived indicators with the risk of developing type 2 diabetes: a Chinese population-based cohort study. Lipids Health Dis 2023;22:24. [PMID: 36788551 DOI: 10.1186/s12944-023-01790-7] [Reference Citation Analysis]
|
| 4 |
Wang X, Wei L, Wu Y, Yan J, Zhao L, Yue X, Gao C. ST-segment elevation predicts the occurrence of malignant ventricular arrhythmia events in patients with acute ST-segment elevation myocardial infarction. BMC Cardiovasc Disord 2023;23:61. [PMID: 36732698 DOI: 10.1186/s12872-023-03099-w] [Reference Citation Analysis]
|
| 5 |
Donniacuo M, De Angelis A, Telesca M, Bellocchio G, Riemma MA, Paolisso P, Scisciola L, Cianflone E, Torella D, Castaldo G, Capuano A, Urbanek K, Berrino L, Rossi F, Cappetta D. Atrial fibrillation: Epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors. Pharmacol Res 2023;188:106591. [PMID: 36502999 DOI: 10.1016/j.phrs.2022.106591] [Reference Citation Analysis]
|
| 6 |
Rachwalik M, Matusiewicz M, Jasiński M, Hurkacz M. Evaluation of the usefulness of determining the level of selected inflammatory biomarkers and resistin concentration in perivascular adipose tissue and plasma for predicting postoperative atrial fibrillation in patients who underwent myocardial revascularisation. Lipids Health Dis 2023;22:2. [PMID: 36624488 DOI: 10.1186/s12944-022-01769-w] [Reference Citation Analysis]
|
| 7 |
Zhou Y, Song X, Ma J, Wang X, Fu H. Association of inflammation indices with left atrial thrombus in patients with valvular atrial fibrillation. BMC Cardiovasc Disord 2023;23:9. [PMID: 36624370 DOI: 10.1186/s12872-023-03036-x] [Reference Citation Analysis]
|
| 8 |
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacol Res 2023;187:106597. [PMID: 36470546 DOI: 10.1016/j.phrs.2022.106597] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Yang L, Zhang X, Wang Q. Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis. Front Endocrinol (Lausanne) 2022;13:992937. [PMID: 36589841 DOI: 10.3389/fendo.2022.992937] [Reference Citation Analysis]
|
| 10 |
Patoulias D, Fragakis N, Rizzo M. The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest. Life (Basel) 2022;12. [PMID: 36556427 DOI: 10.3390/life12122062] [Reference Citation Analysis]
|
| 11 |
Capuano A, Clementi E, Paolisso G. Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.1040649] [Reference Citation Analysis]
|
